Individual InvestorsEmployee Shareholders Institutional InvestorsPrivate Companies Accredited InvestorsSeed & Angel InvestorsAsset Managers & Hedge FundsFamily OfficesVenture Capital FirmsWealth Managers & RIAsWho We Serve Trading Data Liquidity Programs Retirement Individual InvestingForge MarketplaceFind new private company investment opportunities​Browse CompaniesInstitutional TradingForge ProTrade private companies with Forge’s institutional brokerage tool​Forge PriceA proprietary indicative price, calculated daily, for approximately 200 pre-IPO companiesForge DataAnalyze private markets via Forge’s intuitive web application​Forge Private Market Index​Monitor a benchmark for actively traded private companies ​Forge Accuidity Private Market Index​Invest in an institutionally-managed diversified basket of private companies (QPs only)​Liquidity ProgramsRetain and reward employees with company-sponsored liquidity solutions like tender offers and customized programsSelf-Directed IRAForge TrustInvest in private companies and other alternative assets through a tax-advantaged Self-Directed IRAWhat We Do All insights Reports and highlights News and trends Private market education Tips and tutorials Forge Investment OutlookPrivate Market UpdatesIPO calendarPrivate Magnificent 7Emerging trendsPrivate company newsUpcoming IPOsAll guidesPrivate market basicsPrivate shares transactionsValuations, pricing and market trendsSelling in the private marketFAQsGlossaryCompany page and tradesProof of ownershipBid and ask submissionsForge fund offeringsInsights About UsLeadershipInvestor RelationsPeople & CultureCareers About
Log InSign Up
Who We Serve
What We Do
Insights
About
Who We Serve
Individual Investors
Institutional Investors
What We Do
Trading
Individual Investing
Institutional Trading
Data
Liquidity Programs
Retirement
Self-Directed IRA
Insights
Reports and highlights
News and trends
Private market education
Tips and tutorials
About
Log In
Sign Up
Secondary marketplace / Explore private companies / Eikon Therapeutics IPO
Eikon Therapeutics

Eikon Therapeutics IPO

$1.85B
Series D Valuation, Feb 2025
Completed IPO
Learn More About Eikon Therapeutics Stock
Register for details
For more details on financing and valuation of private companies similar to Eikon Therapeutics before its IPO, register or log in today.
Please provide a valid email address.
By registering, you agree to Forge’s Terms of Use. Already registered? Log In

Eikon Therapeutics IPO date and status

2019
Founded
Jan 2026
S-1 Filed
www.sec.gov
Feb 2026
IPO Completed
www.bloomberg.com

Company details

Eikon Therapeutics, based in Hayward, Calif., was founded in 2019 by Eric Betzig, Xavier Darzacq, Luke Lavis, and Robert Tjian. In 2014, Betzig shared the Nobel Prize in Chemistry. Robert Perlmutter is the company’s chairman and CEO. Eikon, which was last valued on January 2022 at $3.1 billion, is a drug discovery and development company that leverages superior engineering and high-performance computing to analyze single molecule protein behavior in living cells.

In January 2022, the company raised $525 million in Series B financing led by more than a dozen investors including T. Rowe Price Associates, Inc., Canada Pension Plan Investment Board, UC Investments, Soros Capital and Schroders Capital.

These comments should not be interpreted to mean that the company is formally pursuing or foregoing an IPO.

eikontx.com
Sector
Healthcare
Subsector
Biotech & Pharma
Founded
2019
Headquarters
Hayward, CA, United States
Forge Price 1
Price not available
Market Activity 2
Limited
Last Matched Price
Get Full Access
Post-Money Valuation 3
$1.85B
Total Funding
$1.16B
Last Funding Round
Series D

Learn more about Eikon Therapeutics

To invest in Eikon Therapeutics pre-IPO

Can you invest in Eikon Therapeutics pre-IPO?

You may invest in Eikon Therapeutics as it is a public company listed on the NASDAQ with ticker EIKN. But if you are an accredited investor interested in buying pre-IPO shares of a private company, you can learn more about how to invest in the private market or register today to get started.

Can you sell shares of Eikon Therapeutics before it goes public?

You can no longer sell shares of Eikon Therapeutics on Forge as this company is no longer private. However, if you own shares of a private company, Forge may be able to help you sell them in a way that works for you and the company. Learn more or register with us today to get started.

What is the pre-IPO value of my Eikon Therapeutics shares?

Forge can no longer determine the value of Eikon Therapeutics shares as this company is no longer private. However, if you own shares of a private company, Forge may help you value and sell them in a way that works for you and the company. Learn more or register with us today to get started.

Is Eikon Therapeutics a publicly traded company?

Eikon Therapeutics became a public company following its IPO on 02/05/2026 and is now traded on the NASDAQ under the ticker EIKN.

To learn more about Eikon Therapeutics potential IPO

Will Eikon Therapeutics go IPO?

Eikon Therapeutics became a public company following its IPO on 02/05/2026 and is now traded on the NASDAQ under the ticker EIKN.

What is Eikon Therapeutics’ IPO price?

The IPO price of Eikon Therapeutics is not currently available.

When was Eikon Therapeutics founded?

Eikon Therapeutics was founded in 2019.

What is Eikon Therapeutics funding to date?

Eikon Therapeutics has raised $1.16B to date.

Eikon Therapeutics major investors

Ame Cloud Ventures
General Catalyst
Horizons Ventures
Innovation Endeavors
Lux Capital
The Column Group

Eikon Therapeutics pre-IPO valuation and funding rounds

Funding history chart
Funding round and deals details
Funding Date Round Amount Raised Price per Share Post-Money Valuation 3 Key Investors
02/14/2025 Series D $350.7MM $5.84 $1.85B Alexandria Venture Investments, Ame Cloud Ventures, E15 Vc, Foresite Capital, General Catalyst, Lux Capital, Soros Capital, Stepstone Group, The Column Group, T. Rowe Price, Uc Investments
Price per Share
$ xx.xx
Shares Outstanding
60,005,669
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
6.0%
Cumulative
Non-cumulative
Participating
Participating
Participation Cap
1000
Key Investors
Alexandria Venture Investments, Ame Cloud Ventures, E15 Vc, Foresite Capital, General Catalyst, Lux Capital, Soros Capital, Stepstone Group, The Column Group, T. Rowe Price, Uc Investments
02/14/2025 Series C-1 $29.08MM $5.84 $1.85B Alexandria Venture Investments, Ame Cloud Ventures, E15 Vc, Foresite Capital, General Catalyst, Lux Capital, Soros Capital, Stepstone Group, The Column Group, T. Rowe Price, Uc Investments
Price per Share
$ xx.xx
Shares Outstanding
4,975,110
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
6.0%
Cumulative
Non-cumulative
Participating
Participating
Participation Cap
1000
Key Investors
Alexandria Venture Investments, Ame Cloud Ventures, E15 Vc, Foresite Capital, General Catalyst, Lux Capital, Soros Capital, Stepstone Group, The Column Group, T. Rowe Price, Uc Investments
02/14/2025 Series B-1 $208.98MM $5.84 $1.85B Alexandria Venture Investments, Ame Cloud Ventures, E15 Vc, Foresite Capital, General Catalyst, Lux Capital, Soros Capital, Stepstone Group, The Column Group, T. Rowe Price, Uc Investments
Price per Share
$ xx.xx
Shares Outstanding
35,756,908
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
6.0%
Cumulative
Non-cumulative
Participating
Participating
Participation Cap
1000
Key Investors
Alexandria Venture Investments, Ame Cloud Ventures, E15 Vc, Foresite Capital, General Catalyst, Lux Capital, Soros Capital, Stepstone Group, The Column Group, T. Rowe Price, Uc Investments
05/18/2023 Series C $111.68MM $21.50 $3.6B Undisclosed Investors
Price per Share
$ xx.xx
Shares Outstanding
5,194,787
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
6.0%
Cumulative
Non-cumulative
Participating
Participating
Participation Cap
1000
Key Investors
Undisclosed Investors
01/06/2022 Series B $308.79MM $17.69 $2.95B Adia, Ame Cloud Ventures, Canada Pension Plan Investment Board, E15 Vc, Ecor1 Capital, Foresite Capital, General Catalyst, Harel Insurance, Hartford Healthcare Endowment, Horizon Ventures, Innovaction Endeavors, Lux Capital, Schroders Capital, Soros Capital, Stepstone Group, The Column Group, T. Rowe Price Associates, Uc Investments
Price per Share
$ xx.xx
Shares Outstanding
17,456,768
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
6.0%
Cumulative
Non-cumulative
Participating
Participating
Participation Cap
1000
Key Investors
Adia, Ame Cloud Ventures, Canada Pension Plan Investment Board, E15 Vc, Ecor1 Capital, Foresite Capital, General Catalyst, Harel Insurance, Hartford Healthcare Endowment, Horizon Ventures, Innovaction Endeavors, Lux Capital, Schroders Capital, Soros Capital, Stepstone Group, The Column Group, T. Rowe Price Associates, Uc Investments
05/05/2021 Series A-1 $102.54MM $2.00 $305.44MM Foresite Capital, Innovation Endeavors, Lux Capital, The Column Group
Price per Share
$ xx.xx
Shares Outstanding
51,268,891
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
6.0%
Cumulative
Non-cumulative
Participating
Participating
Participation Cap
1000
Key Investors
Foresite Capital, Innovation Endeavors, Lux Capital, The Column Group
05/05/2021 Series A $48MM $1.00 $305.44MM Foresite Capital, Innovation Endeavors, Lux Capital, The Column Group
Price per Share
$ xx.xx
Shares Outstanding
48,000,000
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
6.0%
Cumulative
Non-cumulative
Participating
Participating
Participation Cap
1000
Key Investors
Foresite Capital, Innovation Endeavors, Lux Capital, The Column Group

Eikon Therapeutics IPO news and media highlights

BioSpace 06/01/2023

Eikon Acquires Broad Development Pipeline, Raises $106M in Series C Funding

Led by biopharma titan Roger Perlmutter, Eikon Therapeutics kicked off 2022 with a Series B financing worth $517.8 million. The Bay Area-based biotech made another splash Thursday, announcing a $106 million Series C raise and the acquisition of exclusive, global rights to several early- to mid-stage assets.
FierceBiotech 06/01/2023

Eikon snaps up clinical pipeline thanks to 'buyer's market,' while internal pipeline remains covert

Eikon Therapeutics emerged with the promise of Nobel Prize-winning molecule tracking technology. But now, CEO Roger Perlmutter, M.D., Ph.D., and co. are using their more than $600 million war chest for something else: buying up clinical-stage drugs.
The Business Journals 07/31/2022

Biotech company Eikon Therapeutics to open New York City operations base

Eikon Therapeutics, a drug discovery and development company, has signed a lease to open a New York City operations base at the Alexandria Center for Life Science at 430 E. 29th St.
FierceBiotech 06/30/2022

Fierce Next Gen: Eikon drops hints at early pipeline, plans for $660M-plus reservoir

After raising more than $660 million in less than a year, Eikon Therapeutics' future plans are coming into clearer view, with an oncology pipeline underway as the star-studded biotech looks to capitalize on—and expand—Nobel Prize-winning tech.
Browse More Insights

Private companies exploring an IPO

See which private companies are preparing for the public market. Register to get full access to the latest secondary market pricing data.

Sector: Healthcare
Subsector: Biotech & Pharma
Trade Metrics Last Funding Round
Company Forge Price Last Matched Round Post-Money Valuation 3 Price Per Share Amount Raised
Generate BiomedicinesGenerate BiomedicinesNot available$ xx.xxSeries C$2.22B$11.85$399.4MM
OriginOriginNot available$ xx.xxNot available------
Affinia TherapeuticsAffinia TherapeuticsNot available$ xx.xxSeries C$156.61MM$1.62$40MM
See Tech IPO Calendar

Private market movers

Track trading activity and investor momentum across thousands of private companies. Register to view last matched prices and additional transactional details.

Actively traded

Company Forge Price Market Activity Last Matched
Anthropic Anthropic $259.14 -$13.84 (5.07%)High $xxx.xx
OpenAI OpenAI $723.12 +$0.12 (0.02%)High $xxx.xx
SpaceX SpaceX $601.27 +$4.10 (0.69%)High $xxx.xx
Anduril Anduril $110.97 +$4.00 (3.74%)High $xxx.xx
Databricks Databricks $197.66 +$0.01 (0.01%)High $xxx.xx
See All Actively Traded Companies

Artificial Intelligence (AI)

Company Forge Price Market Activity Last Matched
Anthropic Anthropic $259.14 -$13.84 (5.07%)High $xxx.xx
OpenAI OpenAI $723.12 +$0.12 (0.02%)High $xxx.xx
Anduril Anduril $110.97 +$4.00 (3.74%)High $xxx.xx
Databricks Databricks $197.66 +$0.01 (0.01%)High $xxx.xx
Figure AI Figure AI $174.00 -$20.00 (10.31%)Limited $xxx.xx
See All AI Companies

Forge, your trusted partner for pre-IPO insights and Eikon Therapeutics data

Forge is the trusted platform for buying and selling pre-IPO shares. Investors and shareholders worldwide rely on our deep data insights, liquidity solutions, and tailored investment opportunities to navigate the private market. Register to get started.

Register

Updated on: Feb 6, 2026

PLEASE READ THESE IMPORTANT LEGAL NOTICES & DISCLOSURES

  1. Forge Price™ is a custom data-point calculated and disseminated by Forge Data LLC (“Forge Data”) and is a mark of Forge Data. Forge Price may rely on a very limited number of inputs in its calculation. Forge Price is prepared and disseminated solely for informational purposes. Redistribution is permitted solely with Forge’s written consent. While Forge has obtained information from sources it believes to be reliable, Forge does not perform an audit or undertake any duty of due diligence or independent verification of any information it receives. Forge does not guarantee the accuracy, completeness, timeliness, or availability of Forge Price, and are not responsible for any errors or omissions, regardless of the cause, or any results obtained from the use of Forge Price. Forge Price is derived from secondary activity on the Forge platform and other private market trading platforms, and other publicly-available datapoints collected by Forge. Forge Price is not intended to, and does not necessarily, represent the market price of any securities (I.e., the price at which you could buy or sell such securities). Neither reference to company names, nor calculation of Forge Price for a specific company, implies any affiliation between Forge and that company, any endorsement or sponsorship by Forge of any company or vice versa, or any partnership, joint venture or other commercial relationship between Forge and any company. Rights with respect to any company marks referred to herein are owned by the company. The dollar-figure and percentage displayed indicates the per share change in dollar amount and percentage since the most recent Forge Price change. Percentages are rounded to the nearest whole number.
  2. Market activity indicates the level of activity for a company based on recent IOIs, secondary transactions, and pending transactions on Forge.
  3. Post-Money Valuation represents the estimated valuation based on company-submitted Certificates of Incorporations (COIs).
  4. Last Known Valuation represents a valuation gathered from non-COI, publicly available sources including company press releases or multiple concurring news articles.
  5. Actively traded companies are companies with a high market activity with the highest post-money valuation in the same sector.

‘Stock Price’ or other private company metrics (‘PC Data’) may rely on a very limited number of trade and/or IOI inputs in their calculation. PC Data is prepared and disseminated solely for informational purposes. While Forge has obtained information from sources it believes to be reliable, Forge does not perform an audit or undertake any duty of due diligence or independent verification of any information it receives. Forge does not guarantee the accuracy, completeness, timeliness, or availability of PC Data, and are not responsible for any errors or omissions, regardless of the cause, or any results obtained from the use of PC Data. PC Data is derived from the performance and pricing of secondary activity on the Forge platform and other private market trading platforms. PC Data is not intended to, and does not necessarily, represent the market price of any securities (I.e., the price at which you could buy or sell such securities). Reference to company names does not imply any affiliation between Forge and that company, any endorsement or sponsorship by Forge of any company or vice versa, or any partnership, joint venture or other commercial relationship between Forge and any company. Rights with respect to any company marks referred to herein are owned by the company.

The news articles displayed on this page may be curated using artificial intelligence (AI) technology, which selects relevant content from a list of trusted web sources. While we strive for accuracy and reliability, the inclusion of an article does not imply endorsement or verification of its content. This communication is for informational purposes only. Investors should conduct their own research and consult a financial professional before making investment decisions.

Investing in private company securities is not suitable for all investors, is highly speculative, is high risk, and investors should be prepared to withstand a total loss of their investment. Private company securities are highly illiquid and there is no guarantee that a market will develop for such securities. Each investment carries its own risks, and investors should conduct their own due diligence regarding the investment, including obtaining independent professional advice. Past performance is not indicative of future results. This is not a recommendation, offer, solicitation of an offer, or advice to buy or sell securities by Forge, nor an offer of brokerage services in any jurisdiction where Forge is not permitted to offer brokerage services. Brokerage products and services are offered by Forge Securities LLC, a registered broker-dealer and member FINRA/SIPC. Please see other important disclaimers, disclosures and restrictions you acknowledge by using this website and to which you are subject.